Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Long-Term Investments (2023 - 2025)

Cyclerion Therapeutics has reported Long-Term Investments over the past 3 years, most recently at $5.4 million for Q3 2025.

  • Quarterly results put Long-Term Investments at $5.4 million for Q3 2025, changed 0.0% from a year ago — trailing twelve months through Sep 2025 was $5.4 million (changed 0.0% YoY), and the annual figure for FY2024 was $5.4 million, changed 0.0%.
  • Long-Term Investments for Q3 2025 was $5.4 million at Cyclerion Therapeutics, roughly flat from $5.4 million in the prior quarter.
  • Over the last five years, Long-Term Investments for CYCN hit a ceiling of $5.4 million in Q3 2023 and a floor of $5.4 million in Q3 2023.
  • Median Long-Term Investments over the past 3 years was $5.4 million (2023), compared with a mean of $5.4 million.
  • Peak annual rise in Long-Term Investments hit 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
  • Cyclerion Therapeutics' Long-Term Investments stood at $5.4 million in 2023, then changed by 0.0% to $5.4 million in 2024, then changed by 0.0% to $5.4 million in 2025.
  • The last three reported values for Long-Term Investments were $5.4 million (Q3 2025), $5.4 million (Q2 2025), and $5.4 million (Q1 2025) per Business Quant data.